Prime

Type your tag names separated by a space and hit enter

[Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111)].

Abstract

It is established that single intravenous (0.5 and 5 mg/kg, p.o.) or single peroral (10, 50, 100 mg/kg) and prolonged peroral (5 mg/kg, over 10 days) administration of noopept produces a dose-dependent inhibition of the model inflammatory response to concanavaline A in CBA mice. Intravenously injected (5 mg/kg) noopept suppressed the acute nonimmune carrageenan-induced foot inflammation in rats by 62.2% within 3 h. The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively). The in vitro experiments with neutrophilic leukocytes of F1(CBA.C57BL/6) mice treated with noopept in a single dose of 5 mg/kg (i.v.) showed a 5- to 6-fold suppression of the hemiluminescence stimulated by opsoinized zymosan or phorbolmyristate acetate. It is suggested that the antiinflammatory activity of noopept is probably related to its antioxidant properties.

Links

Authors

, , , , ,

Source

MeSH

Animals
Anti-Inflammatory Agents, Non-Steroidal
Antioxidants
Arthritis, Experimental
Chronic Disease
Dipeptides
Edema
Luminescent Measurements
Male
Mice
Mice, Inbred C57BL
Mice, Inbred CBA
Neutrophils
Rats
Reactive Oxygen Species

Pub Type(s)

English Abstract
Journal Article

Language

rus

PubMed ID

12109295

Citation

TY - JOUR T1 - [Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111)]. AU - Kovalenko,L P, AU - Miramedova,M G, AU - Alekseeva,S V, AU - Gudasheva,T A, AU - Ostrovskaia,R U, AU - Seredenin,S B, PY - 2002/7/12/pubmed PY - 2002/8/20/medline PY - 2002/7/12/entrez SP - 53 EP - 5 JF - Eksperimental'naia i klinicheskaia farmakologiia JO - Eksp Klin Farmakol VL - 65 IS - 2 N2 - It is established that single intravenous (0.5 and 5 mg/kg, p.o.) or single peroral (10, 50, 100 mg/kg) and prolonged peroral (5 mg/kg, over 10 days) administration of noopept produces a dose-dependent inhibition of the model inflammatory response to concanavaline A in CBA mice. Intravenously injected (5 mg/kg) noopept suppressed the acute nonimmune carrageenan-induced foot inflammation in rats by 62.2% within 3 h. The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively). The in vitro experiments with neutrophilic leukocytes of F1(CBA.C57BL/6) mice treated with noopept in a single dose of 5 mg/kg (i.v.) showed a 5- to 6-fold suppression of the hemiluminescence stimulated by opsoinized zymosan or phorbolmyristate acetate. It is suggested that the antiinflammatory activity of noopept is probably related to its antioxidant properties. SN - 0869-2092 UR - https://www.unboundmedicine.com/medline/citation/12109295/[Anti_inflammatory_properties_of_noopept__dipeptide_nootropic_agent_GVS_111 L2 - http://www.nlm.nih.gov/medlineplus/antioxidants.html ER -